Insights Into Chronic Lymphocytic Leukemia (CLL) Midwest

Perspectives of community physicians from the midwest region of the United States on the management of newly diagnosed and relapsed/refractory CLL

Midwest – September 30, 2020

Faculty Chair

Susan O’Brien, MD

UC Irvine Medical Center, Orange, CA, US

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report


Factors guiding first-line therapy

  • Impact of biomarkers (del(17p)/TP53 mutation), patient age, performance status, and comorbidities on therapy choice
  • Navigating chemotherapy, chemoimmunotherapy, chemo-free therapy options, and BCR signaling inhibitors
  • MRD: should we check? How? When? And why?
  • MRD and role of maintenance therapy
  • Role of fixed-duration treatment vs treatment until progression

Factors guiding second-line and subsequent therapy

  • Relapsed vs refractory disease
  • Impact of prior therapy on next therapy
  • Monotherapy vs combination therapy
  • Role of treatment discontinuation
  • Is there a role for MRD?


  • A moderated roundtable discussion focusing on treatment of CLL was held on September 30, 2020
  • The group of advisors comprised 12 community oncologists from the midwest region of the US
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.